Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biological target

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    171 result(s) found for: Biological target. Displaying page 6 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2018-002077-21 Sponsor Protocol Number: ICR-CTSU/2017/10065 Start Date*: 2019-04-18
    Sponsor Name:The Institute of Cancer Research
    Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-000379-32 Sponsor Protocol Number: D4200C0007A Start Date*: 2004-09-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untrea...
    Medical condition: Non Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000172-38 Sponsor Protocol Number: NP137-CT-02 Start Date*: 2020-09-04
    Sponsor Name:NETRIS PHARMA
    Full Title: A randomised, multicentre, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological activity (Phase II) of a humanized monoclonal antibody targeting Ne...
    Medical condition: Locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001197 Adenocarcinoma of the cervix PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014987 Epidermoid carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004666-26 Sponsor Protocol Number: 2015/208/HP Start Date*: 2017-07-19
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Randomised double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid
    Medical condition: severe forms of mucous membrane pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002509-21 Sponsor Protocol Number: FIL-Rouge Start Date*: 2017-07-17
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response...
    Medical condition: Advanced stage (IIB-IV) Hodgkin Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005848-16 Sponsor Protocol Number: CS7017-A-E201 Start Date*: 2009-06-16
    Sponsor Name:Daiichi Sankyo Development Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 2 STUDY OF CS-7017 IN COLORECTAL CANCER PATIENTS WHO HAVE ACHIEVED DISEASE CONTROL FOLLOWING FIRST-LINE CHEMOTHERAPY
    Medical condition: Stage III and IV Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002677-53 Sponsor Protocol Number: CL2-78989-009 Start Date*: 2012-12-19
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wa...
    Medical condition: Arterial wall inflammation in patients with marked atherosclerotic plaque inflammation
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10057703 Coronary atherosclerosis of non-autologous biological bypass graft LLT
    16.0 100000004849 10058152 Coronary atherosclerosis of bypass graft LLT
    16.0 100000004866 10018104 Generalized and unspecified atherosclerosis LLT
    16.0 100000004866 10002892 Aortic atherosclerosis LLT
    16.0 100000004849 10011093 Coronary atherosclerosis LLT
    16.0 100000004866 10003603 Atherosclerosis generalized LLT
    16.0 100000004849 10011095 Coronary atherosclerosis of native coronary artery LLT
    16.0 100000004866 10003605 Atherosclerosis of aorta LLT
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    16.0 100000004849 10011094 Coronary atherosclerosis of autologous biological bypass graft LLT
    16.0 100000004849 10011076 Coronary artery atherosclerosis LLT
    16.0 100000004849 10011097 Coronary atherosclerosis of unspecified vessel LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003656-35 Sponsor Protocol Number: E7389-G000-211 Start Date*: 2006-03-14
    Sponsor Name:Eisai Limited
    Full Title: A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to...
    Medical condition: Locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005209-23 Sponsor Protocol Number: CA163139 Start Date*: 2008-03-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/...
    Medical condition: BREAST CANCER, FIRST LINE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: FR (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001220-30 Sponsor Protocol Number: EGF117165 Start Date*: 2014-07-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab i...
    Medical condition: HER2 positive Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001012-68 Sponsor Protocol Number: CA182-006 Start Date*: 2007-04-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients...
    Medical condition: Unresectable, advanced or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004977-10 Sponsor Protocol Number: 08meInnereA_GALACTIC Start Date*: 2013-07-25
    Sponsor Name:University Hospital Basel, Cardiology
    Full Title: Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study
    Medical condition: - acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10054112 Hospitalisation PT
    19.0 10018065 - General disorders and administration site conditions 10011906 Death PT
    19.0 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prohibited by CA) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-005770-26 Sponsor Protocol Number: KRONF2 Start Date*: 2023-10-20
    Sponsor Name:Medical University of Warsaw
    Full Title: Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded f...
    Medical condition: Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000523 Acoustic neuroma PT
    27.0 10010331 - Congenital, familial and genetic disorders 10029271 Neurofibromatosis, type 2 (acoustic neurofibromatosis) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001868-40 Sponsor Protocol Number: SIEGE Start Date*: 2013-11-05
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Scheduling nab-paclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment f...
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001587-19 Sponsor Protocol Number: UHSM0315 Start Date*: 2015-07-15
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk
    Medical condition: We seek to investigate the breast cancer risk reducing properties of ulipristal acetate
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10004746 Biopsy breast normal PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10022891 - Investigations 10071224 Breast scan PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001154-14 Sponsor Protocol Number: Vonoprazan-2001 Start Date*: 2016-05-23
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatm...
    Medical condition: Gastro-Esophageal Reflux Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10017885 Gastrooesophageal reflux disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000388-28 Sponsor Protocol Number: 00658;MK-0683-201 Start Date*: 2011-06-30
    Sponsor Name:University Medical Center Freiburg
    Full Title: Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma
    Medical condition: Relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002945-23 Sponsor Protocol Number: MT203-2004 Start Date*: 2015-02-18
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs A...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Prematurely Ended) EE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013404-32 Sponsor Protocol Number: GFM-clo-08 Start Date*: 2009-07-23
    Sponsor Name:Groupe Francophone des Myélodysplasies (GFM)
    Full Title: A Phase I/II Multicenter Study of IV Clofarabine In Patients with High-Risk Myelodysplastic Syndrome who have failed Therapy with Azacitidine: the NIDEVOL study
    Medical condition: In Patients with High-Risk Myelodysplastic Syndrome who have failed Therapy with Azacitidine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003469-32 Sponsor Protocol Number: UCL/13/0045 Start Date*: 2014-10-13
    Sponsor Name:University College London
    Full Title: A Single Arm Phase II trial of BMN 673 for inoperable, advanced endometrial cancer with retrospective PTEN, MSI and MRE11 analysis.
    Medical condition: Inoperable, advanced, recurrent or metastatic endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 02:53:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA